Isofair: Clinically Proven Oral Isotretinoin for Severe Nodular Acne Resolution
Isofair
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.50 | $50.00 (0%) | 🛒 Add to cart |
| 30 | $1.90 | $75.00 $57.00 (24%) | 🛒 Add to cart |
| 60 | $1.58 | $150.00 $95.00 (37%) | 🛒 Add to cart |
| 90 | $1.52 | $225.00 $137.00 (39%) | 🛒 Add to cart |
| 120 | $1.48 | $300.00 $177.00 (41%) | 🛒 Add to cart |
| 180 | $1.42 | $450.00 $256.00 (43%) | 🛒 Add to cart |
| 270 | $1.30 | $675.00 $351.00 (48%) | 🛒 Add to cart |
| 360 | $1.25
Best per pill | $900.00 $450.00 (50%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.70 | $54.00 (0%) | 🛒 Add to cart |
| 30 | $2.10 | $81.00 $63.00 (22%) | 🛒 Add to cart |
| 60 | $1.90 | $162.00 $114.00 (30%) | 🛒 Add to cart |
| 90 | $1.67 | $243.00 $150.00 (38%) | 🛒 Add to cart |
| 120 | $1.58 | $324.00 $190.00 (41%) | 🛒 Add to cart |
| 180 | $1.49 | $486.00 $269.00 (45%) | 🛒 Add to cart |
| 270 | $1.45 | $729.00 $392.00 (46%) | 🛒 Add to cart |
| 360 | $1.35
Best per pill | $972.00 $486.00 (50%) | 🛒 Add to cart |
Isofair represents a significant advancement in the management of severe, treatment-resistant nodular acne, offering dermatologists a potent retinoid therapy with well-documented efficacy. As an oral formulation containing isotretinoin, it targets the multifactorial pathogenesis of acne through comprehensive sebostatic, anti-inflammatory, and comedolytic mechanisms. This systemic treatment is reserved for cases where conventional therapies—including topical agents and antibiotics—have proven inadequate, providing a definitive solution for patients with disfiguring, recalcitrant disease. Clinical studies consistently demonstrate its capacity to induce long-term remission, fundamentally altering disease course and significantly improving quality of life.
Features
- Contains isotretinoin (13-cis-retinoic acid) in 10mg, 20mg, and 40mg soft gelatin capsules
- Bioavailability enhanced by lipid-rich meals; peak plasma concentrations achieved within 1-4 hours
- Extensive tissue distribution with high affinity for sebaceous glands
- Metabolized primarily via cytochrome P450 pathways (CYP2C8, CYP2C9, CYP3A4)
- Half-life of approximately 21 hours, supporting once-daily dosing
- Manufactured under strict pharmaceutical-grade conditions with batch consistency
- Available in blister packs with clear dosage strength identification
- Includes desiccant in packaging to maintain stability
Benefits
- Achieves profound and sustained reduction in sebum production (up to 90% decrease)
- Induces long-term remission in 85-90% of patients with severe nodular acne
- Dramatically reduces inflammatory lesion count and prevents new comedone formation
- Addresses psychological burden through visible physical improvement
- Minimizes scarring progression by controlling active disease
- Reduces or eliminates dependency on antibiotic therapies and their associated resistance risks
Common use
Isofair is specifically indicated for the treatment of severe recalcitrant nodular acne in patients aged 12 years and older who have not responded adequately to conventional therapy, including systemic antibiotics. It is particularly valuable in cases characterized by multiple inflammatory nodules, extensive truncal involvement, or acne with significant scarring potential. The medication demonstrates exceptional efficacy in acne conglobata, acne fulminans, and other severe variants that profoundly impact both physical health and psychosocial wellbeing. Dermatologists may also consider its use in moderate acne that produces psychological distress or shows scarring tendency, though risk-benefit assessment must be rigorous.
Dosage and direction
The recommended dosage range is 0.5 to 1.0 mg/kg/day administered in two divided doses with meals for 15 to 20 weeks. Treatment should be initiated at 0.5 mg/kg/day with gradual titration based on tolerance and clinical response. For patients with primarily truncal involvement or severe disease, higher doses (up to 2.0 mg/kg/day) may be warranted under close supervision. Capsules must be swallowed whole with a full glass of water and taken with the largest meals of the day to optimize absorption. Duration of therapy is typically continued until a cumulative dose of 120-150 mg/kg is achieved, which correlates with optimal long-term remission rates. Treatment courses should not be repeated within adequate intervals unless clearly justified by persistent severe disease.
Precautions
Isofair is absolutely contraindicated during pregnancy due to its high teratogenic potential. Female patients of reproductive potential must utilize two forms of effective contraception for one month before treatment, throughout therapy, and for one month after discontinuation. Monthly pregnancy testing is mandatory. Regular monitoring of liver enzymes, triglycerides, and cholesterol is essential, particularly in patients with pre-existing metabolic disorders. Patients should be advised regarding potential photosensitivity and the necessity of sun protection. Mood changes, including depression, require immediate evaluation. Dryness of mucous membranes is expected and should be managed with appropriate supportive care. Visual disturbances, particularly night vision impairment, may occur and patients should exercise caution when driving at night.
Contraindications
Absolute contraindications include pregnancy, breastfeeding, and hypersensitivity to isotretinoin or any component of the formulation. Concurrent administration with tetracyclines is prohibited due to increased risk of pseudotumor cerebri. Patients with significantly elevated triglycerides (>800 mg/dL) or hypervitaminosis A should not receive therapy. Severe hepatic impairment (Child-Pugh Class C) precludes use. The medication is contraindicated in patients with history of pancreatitis or hyperlipidemia that cannot be adequately controlled. Women who cannot or will not comply with stringent contraceptive requirements must not receive Isofair.
Possible side effects
The majority of patients experience mucocutaneous effects including cheilitis (90%), xerosis (80%), and conjunctivitis (40%). Common systemic effects include transient elevation of triglycerides (25%) and liver enzymes (15%). Less frequently, patients may report epistaxis, palmoplantar desquamation, or hair thinning. Serious but rare adverse effects include pseudotumor cerebri, inflammatory bowel disease exacerbation, skeletal hyperostosis, and mood alterations. Ocular complications such as corneal opacities and decreased night vision typically resolve upon discontinuation. Pancreatitis occurs in approximately 0.5% of patients, requiring immediate discontinuation.
Drug interaction
Isofair interacts significantly with vitamin A supplements and other retinoids, producing additive toxic effects. Tetracycline antibiotics increase risk of intracranial hypertension and must be avoided. Concurrent use with steroids may potentiate hyperlipidemia. CYP3A4 inducters (phenytoin, carbamazepine) may reduce isotretinoin efficacy, while inhibitors (ketoconazole) may increase toxicity. St. John’s Wort may reduce contraceptive effectiveness, compromising pregnancy prevention requirements. Alcohol consumption may exacerbate triglyceride elevation and hepatotoxicity.
Missed dose
If a dose is missed, patients should take it as soon as remembered with food, unless the next scheduled dose is due within 8 hours. Doubling doses to compensate for missed administration is not recommended. Consistent daily dosing optimizes steady-state concentrations and clinical outcomes. Patients should maintain a dosing diary to enhance adherence, particularly given the teratogenic risks associated with inconsistent contraception during therapy.
Overdose
Acute overdose produces symptoms consistent with hypervitaminosis A: dizziness, headache, vomiting, facial flushing, cheilitis, and abdominal pain. No specific antidote exists; management is supportive with discontinuation of medication. Gastric lavage may be considered if presentation occurs within two hours of ingestion. Hospital observation is recommended for doses exceeding 100 mg/kg due to risk of pancreatitis and intracranial hypertension. Monitoring of electrolytes, liver function, and neurological status should continue for 48 hours.
Storage
Isofair capsules must be stored at controlled room temperature (15-30°C) in their original packaging with desiccant preserved. Protection from light and moisture is essential to maintain stability. Capsules should not be transferred to other containers. Keep strictly out of reach of children and adolescents, particularly due to teratogenic risk. Do not use beyond expiration date printed on packaging. Return unused medication to pharmacy for proper disposal rather than retaining in household.
Disclaimer
Isofair should be prescribed only by physicians experienced in systemic retinoid therapy who understand the serious associated risks. This information does not encompass all possible uses, directions, precautions, or adverse effects. Healthcare providers must review full prescribing information and consult current clinical guidelines before initiation. Patients must receive comprehensive education regarding teratogenic risks and necessary precautions. Treatment decisions must individualize risks and benefits based on specific patient circumstances.
Reviews
“Dramatic improvement in severe conglobate acne after 16 weeks—patient achieved complete remission where multiple antibiotic regimens had failed. Meticulous monitoring essential but results transformative.” - Dermatologist, 15 years experience
“Consistent efficacy across my difficult acne cases. The 10mg option allows better titration for sensitive patients. Requires substantial patient education but delivers unparalleled results.” - Clinical Dermatologist
“Life-changing for patients with scarring acne, but the monitoring burden is significant. Laboratory surveillance and pregnancy prevention program compliance are non-negotiable.” - Academic Dermatologist
“Superior bioavailability compared to some generic formulations. Patients report more predictable response and fewer gastrointestinal complaints. Worth the premium for severe cases.” - Dermatology Specialist